PLoS ONE：岩藻多糖可改善肠炎
原标题：岩藻多糖提取物可改善肠炎
①肠炎（IBD）是一种非常常见的疾病，显著影响人们的生活质量，目前的治疗方法都不能维持长期的临床症状缓解，而且具有一定的副作用；
②岩藻多糖是来自于褐藻中的含硫酸基的多糖物质，具有广泛的生物活性，包括抗炎作用；
③本文利用肠炎小鼠模型，研究了岩藻多糖对肠炎的改善效果；
④实验结果显示，岩藻多糖有效地改善小鼠结肠炎，缓解相应症状，包括维持体重、减少腹泻及减轻便血症状；同时，结肠和脾脏的重量相比对照组显著减小，证明炎症及水肿症状减轻；
结论：岩藻多糖能够显著改善肠炎症状，可以被作为一种新型缓解肠炎的功能食品。
延伸阅读
PLoS ONE 2015, 10: e0128453
Fucoidan Extracts Ameliorate Acute Colitis
Abstract:
Inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease, are an important cause of morbidity and impact significantly on quality of life. Overall, current treatments do not sustain a long-term clinical remission and are associated with adverse effects, which highlight the need for new treatment options. Fucoidans are complex sulphated, fucose-rich polysaccharides, found in edible brown algae and are described as having multiple bioactivities including potent anti-inflammatory effects. Therefore, the therapeutic potential of two different fucoidan preparations, fucoidan-polyphenol complex (Maritech Synergy) and depyrogenated fucoidan (DPF) was evaluated in the dextran sulphate sodium (DSS) mouse model of acute colitis. Mice were treated once daily over 7 days with fucoidans via oral (Synergy or DPF) or intraperitoneal administration (DPF). Signs and severity of colitis were monitored daily before colons and spleens were collected for macroscopic evaluation, cytokine measurements and histology. Orally administered Synergy and DPF, but not intraperitoneal DPF treatment, significantly ameliorated symptoms of colitis based on retention of body weight, as well as reduced diarrhoea and faecal blood loss, compared to the untreated colitis group. Colon and spleen weight in mice treated with oral fucoidan was also significantly lower, indicating reduced inflammation and oedema. Histological examination of untreated colitis mice confirmed a massive loss of crypt architecture and goblet cells, infiltration of immune cells and oedema, while all aspects of this pathology were alleviated by oral fucoidan. Importantly, in this model, the macroscopic changes induced by oral fucoidan correlated significantly with substantially decreased production of at least 15 proinflammatory cytokines by the colon tissue. Overall, oral fucoidan preparations significantly reduce the inflammatory pathology associated with DSS-induced colitis and could therefore represent a novel nutraceutical option for the management of IBD.
First Authors:
Qi Ying Lean
Correspondence:
Nuri Gueven
All Authors:
Qi Ying Lean, Rajaraman D. Eri, J. Helen Fitton, Rahul P. Patel, Nuri Gueven.
2015-06-17 Article
